secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001437749-23-023068
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics Q2 net loss $4.0M; first AJ201 patient dosed, FDA agrees on tramadol Phase 3 design
--------------------------------------------------------------------------------

- Net loss of $4.0M ($0.52 per share) vs $0.6M ($0.41) in Q2 2022; cash $1.6M down from $6.7M at year-end 2022.
- First patient dosed in Phase 1b/2a trial of AJ201 for SBMA; topline data expected H1 2024.
- BAER-101 preclinical results show full seizure suppression at 0.3 mg/kg in GAERS model; Phase 2a planned for 2024.
- FDA alignment on Phase 3 safety study design for IV tramadol; subject to financing, company aims to start soon.
- R&D expense surged to $3.0M from $0.2M; G&A $0.9M vs $0.5M, reflecting clinical progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/atxi20230530_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer